Ubiquinol-10 ameliorates mitochondrial encephalopathy associated with CoQ deficiency

Coenzyme Q10 (CoQ 10 ) deficiency (MIM 607426 ) causes a mitochondrial syndrome with variability in the clinical presentations. Patients with CoQ 10 deficiency show inconsistent responses to oral ubiquinone-10 supplementation, with the highest percentage of unsuccessful results in patients with neurological symptoms (encephalopathy, cerebellar ataxia or multisystemic disease). Failure in the ubiquinone-10 treatment may be the result of its poor absorption and bioavailability, which may be improved by using different pharmacological formulations. In a mouse model ( Coq9 X/X ) of mitochondrial encephalopathy due to CoQ deficiency, we have evaluated oral supplementation with water-soluble formulations of reduced (ubiquinol-10) and oxidized (ubiquinone-10) forms of CoQ 10 . Our results show that CoQ 10 was increased in all tissues after supplementation with ubiquinone-10 or ubiquinol-10, with the tissue levels of CoQ 10 with ubiquinol-10 being higher than with ubiquinone-10. Moreover, only ubiquinol-10 was able to increase the levels of CoQ 10 in mitochondria from cerebrum of Coq9 X/X mice. Consequently, ubiquinol-10 was more efficient than ubiquinone-10 in increasing the animal body weight and CoQ-dependent respiratory chain complex activities, and reducing the vacuolization, astrogliosis and oxidative damage in diencephalon, septum–striatum and, to a lesser extent, in brainstem. These results suggest that water-soluble formulations of ubiquinol-10 may improve the efficacy of CoQ 10 therapy in primary and secondary CoQ 10 deficiencies, other mitochondrial diseases and neurodegenerative diseases. • Ubiquinol-10 has better tissue and mitochondrial uptake than ubiquinone-10. • Ubiquinol-10 is more efficient than ubiquinone-10 in improving cerebral mitochondrial function. • Ubiquinol-10 is more efficient than ubiquinone-10 in reducing oxidative damage vacuolization and astrogliosis.